Management of DIC in APL
Key Point
All-trans retinoic acid (ATRA) is the drug of choice for acute promyelocytic leukemia (APL) and is uniquely effective in resolving DIC associated with this malignancy.
Mechanism in APL-DIC
- 1.
ATRA mechanism: Induces differentiation of abnormal promyelocytes into mature neutrophils, reducing the release of procoagulant substances (tissue factor, cancer procoagulant) from leukemic cells.
- 2.
DIC resolution: As leukemic burden decreases and cells differentiate, the trigger for DIC (release of thromboplastic substances) is eliminated.
- 3.
Rapid effect: ATRA produces clinical improvement in coagulopathy within days to weeks.
Why ATRA is Superior
| Feature | ATRA | Chemotherapy Alone |
|---|
| Mechanism | Differentiation therapy | Cytotoxic (worsens DIC initially) |
| DIC course | Improves rapidly | May worsen before improving |
| Leukostasis risk | Lower | Higher with chemotherapy |
| Induction remission rate | ~90% when combined with chemotherapy | Lower as monotherapy |
High-YieldNEET PG
ATRA + arsenic trioxide (ATO) is now the preferred induction regimen in many centers, with superior outcomes and lower toxicity compared to ATRA + chemotherapy.
Clinical Pearl
In APL-DIC, supportive care (FFP, cryoprecipitate, platelets, low-dose heparin if indicated) is given concurrently with ATRA to manage coagulopathy while the underlying disease is treated.
Differentiation Syndrome (ATRA Toxicity)
ATRA can cause differentiation syndrome (formerly "retinoic acid syndrome") — fever, respiratory distress, weight gain, pulmonary infiltrates — managed with dexamethasone.
